GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » Cash Flow for Dividends

Beximco Pharmaceuticals (DHA:BXPHARMA) Cash Flow for Dividends : BDT-1,582 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals Cash Flow for Dividends?

Beximco Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2024 was BDT-1,567 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2024 was BDT-1,582 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Beximco Pharmaceuticals's quarterly payment of dividends declined from Jun. 2023 (BDT-14 Mil) to Dec. 2023 (BDT0 Mil) but then increased from Dec. 2023 (BDT0 Mil) to Mar. 2024 (BDT-1,567 Mil).

Beximco Pharmaceuticals's annual payment of dividends increased from Jun. 2021 (BDT-578 Mil) to Jun. 2022 (BDT-1,623 Mil) but then declined from Jun. 2022 (BDT-1,623 Mil) to Jun. 2023 (BDT-1,568 Mil).


Beximco Pharmaceuticals Cash Flow for Dividends Historical Data

The historical data trend for Beximco Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Cash Flow for Dividends Chart

Beximco Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -505.35 -601.96 -578.35 -1,623.10 -1,567.92

Beximco Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 -1,552.70 -14.45 - -1,567.08

Beximco Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-1,582 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beximco Pharmaceuticals Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.


Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Traded in Other Exchanges
Address
19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines